Related Experiment Video
Updated: May 19, 2026
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
Published on: October 14, 2016
Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma
Vaibhav Saini1, Curtis D Hose, Anne Monks
1Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute at Frederick, Frederick, Maryland, United States of America.
Abstract:
Recently, there has been renewed interest in the role of tumor stem cells (TSCs) in tumorigenesis, chemoresistance, and relapse of malignant tumors including osteosarcoma. The potential exists to improve osteosarcoma treatment through characterization of TSCs and identification of therapeutic targets. Using transcriptome, proteome, immunophenotyping for cell-surface markers, and bioinformatic analyses, heterogeneous expression of previously reported TSC or osteosarcoma markers, such as CD133, nestin, POU5F1 (OCT3/4), NANOG, SOX2, and aldehyde dehydrogenase, among others, was observed in vitro. However, consistently significantly lower CD326, CD24, CD44, and higher ABCG2 expression in TSC-enriched as compared with un-enriched osteosarcoma cultures was observed. In addition, consistently higher CBX3 expression in TSC-enriched osteosarcoma cultures was identified. ABCA5 was identified as a putative biomarker of TSCs and/or osteosarcoma. Lastly, in a high-throughput screen we identified epigenetic (5-azacytidine), anti-microtubule (vincristine), and anti-telomerase (3,11-difluoro-6,8,13-trimethyl- 8H-quino [4,3,2-kl] acridinium methosulfate; RHPS4)-targeted therapeutic agents as candidates for TSC ablation in osteosarcoma.
Insights
Tumor stem cells (TSCs) drive osteosarcoma growth and relapse. Researchers identified novel biomarkers like ABCA5 and potential therapies including epigenetic and anti-microtubule agents for TSC ablation.
Area of Science:
- Oncology
- Cancer Stem Cell Biology
- Biomarker Discovery
Background:
- Tumor stem cells (TSCs) are implicated in osteosarcoma tumorigenesis, chemoresistance, and relapse.
- Targeting TSCs offers a promising strategy to improve osteosarcoma treatment outcomes.
Purpose of the Study:
- To characterize osteosarcoma TSCs and identify potential therapeutic targets.
- To investigate the expression profiles of known and novel TSC markers in osteosarcoma.
Main Methods:
- Transcriptome, proteome, and immunophenotyping analyses were performed on osteosarcoma cultures.
- Bioinformatic analyses were used to identify differentially expressed markers.
- High-throughput screening identified potential therapeutic agents for TSC ablation.
Main Results:
- Heterogeneous expression of known TSC markers (CD133, nestin, POU5F1, NANOG, SOX2) was observed.
- Significantly lower CD326, CD24, CD44, and higher ABCG2 expression in TSC-enriched cultures.
- ABCA5 was identified as a potential biomarker for osteosarcoma TSCs.
- Epigenetic, anti-microtubule, and anti-telomerase agents showed promise for TSC ablation.
Conclusions:
- Osteosarcoma TSCs exhibit distinct surface marker profiles, including higher CBX3 and potentially ABCA5 expression.
- Novel therapeutic strategies targeting identified markers and pathways are warranted.
- Epigenetic, anti-microtubule, and anti-telomerase agents represent promising candidates for osteosarcoma TSC-targeted therapy.
